Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex

The small natural product rapamycin, when bound to FKBP12, is a potent inhibitor of an evolutionarily conserved Target of Rapamycin Complex 1 (TORC1), which plays a central role in mediating cellular response to nutrient availability. Given the prominent role of TORC1 in cell growth and proliferation, clinical trials have explored the possibility of using rapamycin as an anticancer agent. Unfortunately, the percentage of patients responding favorably has been low, intensifying the need to find biomarkers able to predict rapamycin sensitivity or resistance. In this study, we elucidate the molecular mechanism underlying partial rapamycin resistance in yeast. Using the yeast deletion collection, we identified 15 deletion strains leading to partial rapamycin resistance. Among these were Cu/Zn-superoxide dismutase Sod1, copper transporter Ctr1, and copper chaperone Lys7, suggesting a role for oxidative stress in rapamycin resistance. Further analysis revealed that all 15 strains exhibit elevated levels of superoxide anions, and we show that elevated levels of reactive oxygen species specifically modify TORC1 such that it is no longer able to fully bind FKBP12:rapamycin. Therefore, elevated oxidative stress modifies TORC1 and prevents its binding to the FKBP12:rapamycin complex, ultimately leading to rapamycin resistance. These results warrant an examination into whether similar reasons explain rapamycin resistance observed in various clinical samples.

[1]  Suzanne F. Jones,et al.  Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Lackman,et al.  Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy , 2008, Modern Pathology.

[3]  S. Horvath,et al.  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.

[4]  Robbie Loewith,et al.  Sch9 is a major target of TORC1 in Saccharomyces cerevisiae. , 2007, Molecular cell.

[5]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[6]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[7]  D. Sabatini,et al.  Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.

[8]  D. Sabatini,et al.  Redox Regulation of the Nutrient-sensitive Raptor-mTOR Pathway and Complex* , 2005, Journal of Biological Chemistry.

[9]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Fonseca,et al.  Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Grzesiek,et al.  The Solution Structure of the FATC Domain of the Protein Kinase Target of Rapamycin Suggests a Role for Redox-dependent Structural and Cellular Stability* , 2005, Journal of Biological Chemistry.

[12]  Fulai Jin,et al.  Insights into TOR function and rapamycin response: chemical genomic profiling by using a high-density cell array method. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[14]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[15]  G. Mills,et al.  Determinants of Rapamycin Sensitivity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[16]  D. A. Foster,et al.  Phospholipase D confers rapamycin resistance in human breast cancer cells , 2003, Oncogene.

[17]  Jingxia Li,et al.  Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C. , 2002, Cancer research.

[18]  Ronald W. Davis,et al.  The Ume6 regulon coordinates metabolic and meiotic gene expression in yeast , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Crespo,et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.

[20]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[21]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[22]  A. Levitzki,et al.  ROS, stress‐activated kinases and stress signaling in cancer , 2002, EMBO reports.

[23]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Johnston,et al.  A chemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR). , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Heitman,et al.  The TOR signaling cascade regulates gene expression in response to nutrients. , 1999, Genes & development.

[26]  J. Mccusker,et al.  Three new dominant drug resistance cassettes for gene disruption in Saccharomyces cerevisiae , 1999, Yeast.

[27]  P. Houghton,et al.  Studies on the mechanism of resistance to rapamycin in human cancer cells. , 1998, Molecular pharmacology.

[28]  K. Machida,et al.  Farnesol-Induced Generation of Reactive Oxygen Species via Indirect Inhibition of the Mitochondrial Electron Transport Chain in the Yeast Saccharomyces cerevisiae , 1998, Journal of bacteriology.

[29]  P. Philippsen,et al.  Additional modules for versatile and economical PCR‐based gene deletion and modification in Saccharomyces cerevisiae , 1998, Yeast.

[30]  R. Casareno,et al.  The Copper Chaperone for Superoxide Dismutase* , 1997, The Journal of Biological Chemistry.

[31]  V. Bindokas,et al.  Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  J. Heitman,et al.  TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin (*) , 1995, The Journal of Biological Chemistry.

[33]  A. Mitchell,et al.  Regulation of glutamine-repressible gene products by the GLN3 function in Saccharomyces cerevisiae , 1984, Molecular and cellular biology.

[34]  J. Doroshow,et al.  CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. , 2004, Cancer.